Objective:To investigate the impact of plasmapheresis therapy on the clinical efficacy in predicted severe hypertriglyceridemia-associated acute pancreatitis (HTG-AP) patients.Methods:The clinical data of 500 HTG-AP patients admitted to 36 medical centers across China in the Chinese Acute Pancreatitis Clinical Trials Group-PERFORM database from November 2020 to June 2023 were retrospectively analyzed. Besides the inclusion and exclusion criteria from PERFORM study, patients who had acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score ≥8 or CRP>150 mg/L on admission were included in the final analyses ( n=189). Patients were categorized into the plasmapheresis group ( n=51) and the routine treatment group ( n=138) according to the triglyceride-lowering therapies they received. General data, laboratory findings, AP severity, and clinical outcomes were recorded. Results:Patients undergoing plasmapheresis had higher initial triglyceride levels, APACHEⅡ score, SOFA score, and more organ failure than those receiving routine medical treatment. Results of multivariable logistic regression models showed that the plasmapheresis group, as compared to the routine treatment group, was neither associated with decreased risk of persistent organ failure within 14 days [54.9% (28/51) vs 37.7% (52/138), OR=0.89, 95% CI 0.36-2.21, P=0.810], nor with reduced incidence of organ failure on day 7 [17.7% (9/51) vs 15.9% (22/138), OR=0.60, 95% CI 0.19-1.88, P=0.378]. There was no significant difference on the dynamic changes of serum triglyceride within the first three days of admission ( P=0.108). Conclusions:Early plasmapheresis is not associated with reduced incidence of persistent organ failure in predicted severe HTG-AP patients.

Objective:To investigate the impact of plasmapheresis therapy on the clinical efficacy in predicted severe hypertriglyceridemia-associated acute pancreatitis (HTG-AP) patients.Methods:The clinical data of 500 HTG-AP patients admitted to 36 medical centers across China in the Chinese Acute Pancreatitis Clinical Trials Group-PERFORM database from November 2020 to June 2023 were retrospectively analyzed. Besides the inclusion and exclusion criteria from PERFORM study, patients who had acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score ≥8 or CRP>150 mg/L on admission were included in the final analyses ( n=189). Patients were categorized into the plasmapheresis group ( n=51) and the routine treatment group ( n=138) according to the triglyceride-lowering therapies they received. General data, laboratory findings, AP severity, and clinical outcomes were recorded. Results:Patients undergoing plasmapheresis had higher initial triglyceride levels, APACHEⅡ score, SOFA score, and more organ failure than those receiving routine medical treatment. Results of multivariable logistic regression models showed that the plasmapheresis group, as compared to the routine treatment group, was neither associated with decreased risk of persistent organ failure within 14 days [54.9% (28/51) vs 37.7% (52/138), OR=0.89, 95% CI 0.36-2.21, P=0.810], nor with reduced incidence of organ failure on day 7 [17.7% (9/51) vs 15.9% (22/138), OR=0.60, 95% CI 0.19-1.88, P=0.378]. There was no significant difference on the dynamic changes of serum triglyceride within the first three days of admission ( P=0.108). Conclusions:Early plasmapheresis is not associated with reduced incidence of persistent organ failure in predicted severe HTG-AP patients.

Neuromuscular electrical stimulation (NMES) has been proven to promote human balance, but research on its impact on motor ability mainly focuses on external physical analysis, with little analysis on the intrinsic neural regulatory mechanisms. This study, for the first time, investigated the effects of NMES on cortical activity and cortico-muscular functional coupling (CMFC) during standing balance. Twelve healthy subjects were recruited in bilateral NMES training, with each session consisting of 60 electrically induced isometric contractions. Electroencephalogram (EEG) signals, electromyogram (EMG) signals, and center of pressure (COP) signals of the foot sole were collected before stimulation, two weeks after stimulation, and four weeks after stimulation while the subjects maintained standing balance. The results showed that NMES training improved subjects' postural stability during standing balance. Additionally, based on the EMG power spectral density (PSD), the κ frequency band was defined, and EEG-EMG time-frequency maximal information coefficients (TFMIC) were calculated. It was found that NMES enhanced functional connectivity between the cortex and lower limb muscles, with varying degrees of increase in β-κ and γ-κ frequency band CMFC after stimulation. Furthermore, sample entropy (SE) of EEG signals also increased after training. The results of this study confirm that NMES training can enhance CMFC and brain activation during standing balance. This study, from the perspective of physiological electrical signals, validates the effectiveness of NMES for balance training and provides objective assessment metrics for the training effects of NMES.
Humans ; Postural Balance/physiology* ; Electromyography ; Electroencephalography ; Muscle, Skeletal/physiology* ; Electric Stimulation ; Motor Cortex/physiology* ; Male ; Standing Position ; Adult ; Female

Objective:To investigate the clinical characteristics of first-episode and recurrent acute hypertriglyceridemic pancreatitis (HTGP).Methods:The retrospective cohort study was con-ducted. The clinical data of 313 patients with HTGP admitted to 26 medical centers in China in the Chinese Acute Pancreatitis Clinical Research Group (CAPCTG)-PERFORM database from November 2020 to December 2021 were collected. There were 219 males and 94 females, aged 38(32,44)years. Of the 313 patients, 193 patients with first-episode HTGP were allocated into the first-episode group and 120 patients with recurrent HTGP were allocated into the recurrent group. Observation indica-tors: (1) propensity score matching and comparison of general data of patients between the two groups after matching; (2) comparison of severity and prognosis in the course of disease within 14 days between the two groups; (3) the association between recurrent HTGP and the risk of persistent organ failure (POF); (4) follow-up. Measurement data with normal distribution were represented as Mean± SD, and comparison between groups was conducted using the independent sample t test. Measurement data with skewed distribution were represented as M( Q1, Q3), and comparison between groups was conducted using the Wilcoxon rank sum test. Count data were expressed as absolute numbers or percentages, and comparison between groups was conducted using the chi-square test. Comparison of ordinal data was conducted using the Wilcoxon rank sum test. The Kaplan-Meier method was used to plot the cumulative recurrence rate curve and Log-Rank test was used for survival analysis. The Logistic regression model was used for multivariate analysis, and continuous variables were converted into categorical variables according to the mean value or common criteria. Propensity score matching was performed by 1∶1 nearest neighbor matching method, with caliper value of 0.02. Paired t test or Wilcoxon rank sum test and McNemar′s test were used for comparison between matched groups. Results:(1) Propensity score matching and comparison of general data of patients between the two groups after matching. Of the 313 patients,208 cases were successfully matched, including 104 cases in the first-episode group and 104 cases in the recurrent group. After propensity score matching, there was no significant difference in demographic characteristics, severity of illness scores and laboratory test between the two groups ( P>0.05). The elimination of gender, acute physiology and chornic health evaluation (APACHE) Ⅱ score, computed tomography severity index score, systemic inflammatory response syndrome score, sequential organ failure assessment score, apolipoprotein E, C-reactive protein, creatinine, lactic acid dehydrogenase, procal-citonin confounding bias ensured comparability between the two groups. (2) Comparison of severity and prognosis in the course of disease within 14 days between the two groups. There were signifi-cant differences in POF and local complications between the first-episode group and the recurrent group ( P<0.05). (3) The association between recurrent HTGP and the risk of POF. Results of uncor-rected univariate analysis showed that there was no association between recurrent HTGP and the risk of POF ( odds ratio=0.78, 95% confidence interval as 0.46-1.30, P>0.05). Results of multivariate analysis after adjusting for covariates such as gender, age, APACHE Ⅱ score, C-reactive protein, triglyceride and total cholesterol showed that compared with first-episode HTGP, recurrent HTGP was associated with a higher risk of POF ( odds ratio=2.22, 95% confidence interval as 1.05-4.71, P<0.05). Results of subgroup analysis showed that age<40 years was associated with an increased risk of POF ( odds ratio=3.31, 95% confidence interval as 1.09-10.08, P<0.05). (4) Follow-up. Twelve of the 313 patients died during hospitalization, including 9 cases in the first-episode group and 3 cases in the recurrent group. The rest of 301 surviving patients, including 184 cases in the first-episode group and 117 cases in the recurrent group, were followed up for 19.2(15.5, 21.9)months. Results of follow-up showed that for 184 survived patients of the first-episode group, 164 cases were followed up and 24 cases experienced recurrence, for 117 survived patients of the recurrent group,29 cases experienced recurrence, showing a significant difference between the two groups ( χ2=4.67, P<0.05). Conclusion:Compared with first-episode HTGP, patients with recurrent HTGP are more prone to POF and local complications, and are more prone to recurrence after discharge. The risk of POF in recurrent HTGP patients is 2.22 times that of those with first-episode, and the risk is higher in patients with age <40 years.

Adaptation, Psychological ; Adolescent ; COVID-19 ; Child ; China ; Cross-Sectional Studies ; Female ; Humans ; Male ; SARS-CoV-2

Objective:To investigate the protein expressions of RCAS1/EBAG9 and P53 in intrahepatic cholangiocarcinoma(ICC)tissue and their clinical significance.Methods:The protein expressions of RCAS1/EBAG9 and P53 in 41 specimens of ICC tissue and 9 specimens of normal bile duct tissue were detected by immunohistochemcal staining.The relations of RCAS1/EBAG9 and P53 protein expressions with the clinicopathologic characteristics and prognosis of the patients were analyzed.Results:The positive expression rates of both RCAS1/EBAG9 and P53 proteins in ICC tissue were significantly higher than those in normal bile duct tissue(both P<0.05).The RCAS1/EBAG9 protein expression was significantly related to tumor size,pathological grade,TNM stage and lymph node metastasis,while P53 protein expression was significantly associated with tumor size,pathological grade,and TNM stage(all P<0.05).There was a positive correlation between RCAS1/EBAG9 and P53 protein expression in ICC tissue(r=0.329,P=0.018).The overall postoperative survival time in patients with negative RCAS1/EBAG9 or P53 protein expression was significantly longer than that in patients with positive RCAS1/EBAG9 or P53 protein expression(χ2=3.862,P=0.049;χ2=4.977,P=0.026).Results of univariate and multivariate Cox regression analysis showed that RCAS1/EBAG9 protein expression was an independent risk factor for the prognosis of ICC patients(HR=3.657,95%CI=1.111-12.040,P=0.033).Conclusion:The RCAS1/EBAG9 and P53 protein expressions are increased in ICC tissue,and are closely associated with unfavorable clinicopathologic features and outcomes of the ICC patients,in which,the RCAS1/EBAG9 may probably play a causal role.

Objective:To investigate the protein expressions of RCAS1/EBAG9 and P53 in intrahepatic cholangiocarcinoma(ICC)tissue and their clinical significance.Methods:The protein expressions of RCAS1/EBAG9 and P53 in 41 specimens of ICC tissue and 9 specimens of normal bile duct tissue were detected by immunohistochemcal staining.The relations of RCAS1/EBAG9 and P53 protein expressions with the clinicopathologic characteristics and prognosis of the patients were analyzed.Results:The positive expression rates of both RCAS1/EBAG9 and P53 proteins in ICC tissue were significantly higher than those in normal bile duct tissue(both P<0.05).The RCAS1/EBAG9 protein expression was significantly related to tumor size,pathological grade,TNM stage and lymph node metastasis,while P53 protein expression was significantly associated with tumor size,pathological grade,and TNM stage(all P<0.05).There was a positive correlation between RCAS1/EBAG9 and P53 protein expression in ICC tissue(r=0.329,P=0.018).The overall postoperative survival time in patients with negative RCAS1/EBAG9 or P53 protein expression was significantly longer than that in patients with positive RCAS1/EBAG9 or P53 protein expression(χ2=3.862,P=0.049;χ2=4.977,P=0.026).Results of univariate and multivariate Cox regression analysis showed that RCAS1/EBAG9 protein expression was an independent risk factor for the prognosis of ICC patients(HR=3.657,95%CI=1.111-12.040,P=0.033).Conclusion:The RCAS1/EBAG9 and P53 protein expressions are increased in ICC tissue,and are closely associated with unfavorable clinicopathologic features and outcomes of the ICC patients,in which,the RCAS1/EBAG9 may probably play a causal role.

Keloid scars are often considered aesthetically unattractive and frustrating problems that occur following injuries. They cause functional and cosmetic deformities, displeasure, itching, pain, and psychological stress and possibly affect joint movement. The combination of these factors ultimately results in a compromised quality of life and diminished functional performance. Various methods have been implemented to improve keloid scars using both surgical and non-surgical approaches. However, it has proven to be a challenge to identify a universal treatment that can deliver optimal results for all types of scars. Through a PubMed search, we explored most of the literature that is available about the intralesional injection treatment of hypertrophic scars and keloids and highlights both current (corticosteroid, 5-fluorouracil, bleomycin, interferon, cryotherapy and verapamil) and future treatments (interleukin-10 and botulinum toxin type A). The reference lists of retrieved articles were also analysed. Information was gathered about the mechanism of each injection treatment, its benefits and associated adverse reactions, and possible strategies to address adverse reactions to provide reliable guidelines for determining the optimal treatment for particular types of keloid scars. This article will benefit practitioners by outlining evidence-based treatment strategies using intralesional injections for patients with hypertrophic scars and keloids.
Bleomycin ; Botulinum Toxins ; Cicatrix ; Cicatrix, Hypertrophic ; Congenital Abnormalities ; Cryotherapy ; Fluorouracil ; Humans ; Injections, Intralesional* ; Interferons ; Joints ; Keloid* ; Pruritus ; Quality of Life ; Stress, Psychological ; Treatment Outcome